Primary completion· ClinicalTrials.gov
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Foralumab History and Updates
28 events · 2017 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
0
FDA Approvals
0
Label Revisions
28
Trial Milestones
0
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-11Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Foralumab since 2017, drawn from openFDA, ClinicalTrials.gov, and PubMed.
Upcoming & expected milestones
Primary completion· ClinicalTrials.gov
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Past events
2026
Primary completion· ClinicalTrials.gov
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
2025
Primary completion· ClinicalTrials.gov
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Trial started· ClinicalTrials.gov
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Trial started· ClinicalTrials.gov
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Trial registered· ClinicalTrials.gov
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Trial registered· ClinicalTrials.gov
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
Trial registered· ClinicalTrials.gov
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Trial started· ClinicalTrials.gov
Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Trial registered· ClinicalTrials.gov
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
2024
Trial registered· ClinicalTrials.gov
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Trial registered· ClinicalTrials.gov
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
2023
Trial started· ClinicalTrials.gov
A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
Primary completion· ClinicalTrials.gov
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
2022
Primary completion· ClinicalTrials.gov
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Primary completion· ClinicalTrials.gov
In-patient COVID-19 Study of Intranasal Foralumab
Trial started· ClinicalTrials.gov
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Trial started· ClinicalTrials.gov
In-patient COVID-19 Study of Intranasal Foralumab
2021
Trial started· ClinicalTrials.gov
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Trial registered· ClinicalTrials.gov
Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS
Trial registered· ClinicalTrials.gov
A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease
Trial registered· ClinicalTrials.gov
In-patient COVID-19 Study of Intranasal Foralumab
2019
Primary completion· ClinicalTrials.gov
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
2018
Primary completion· ClinicalTrials.gov
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
Trial started· ClinicalTrials.gov
Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
2017
Trial started· ClinicalTrials.gov
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
Trial registered· ClinicalTrials.gov
Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.